Power loading: a drug for rare forms of muscular dystrophy has been tested in the Russian ...
According to the scientists of the National Research University "BelSU", the obtained results allow us to conclude that the ...
labiotech4 天
Ten first-in-class drugs on track for FDA approval in 2025
As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...
GEN5 天
JPM: Roche Licenses Dyno Therapeutics’ AAV Vector for Neurological Gene Therapy
Roche has exercised its option to license a novel capsid from Dyno Therapeutics for use in a gene therapy program for an ...
Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again
Undervalued biotech company Regenxbio Inc. shows promise with cutting-edge gene therapy technology for AMD and MPS II. Click ...
Insmed’s gene therapy poised to challenge DMD landscape after IND clearance
Currently, the DMD treatment landscape includes Sarepta’s Elevidys (delandistrogene moxeparvovec), the first FDA-approved ...
technologynetworks6 天
Solutions for AAV Research & Development: AAV Titration and Anti-AAV Antibody ELISA Kits
Explore our new AAV Titer ELISA and AAV Antibody Assay Kits, designed for exceptional specificity, sensitivity, and accuracy ...
First Participants Randomized In Askbio Phase II Gene Therapy Trial For Parkinson’S Disease
Berlin, Germany, and Research Triangle Park, N.C., USA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Not intended for UK <a target=_blank href=https ...
bovnews6 天
This Biotech Partnership Could Be the Catalyst REGENXBIO (RGNX) Needs—But What’s Next?
The partnership between REGENXBIO and Nippon Shinyaku is more than just a standard collaboration—it’s a bold, forward-looking venture aimed at bringing revolutionary gene therapies to market for rare, ...